Skip to main content
Ampio asked by FDA for new trial of knee osteoarthritis therapy

The FDA has required Ampio Pharmaceuticals to conduct a new clinical study for Ampion in knee osteoarthritis patients to support its marketing application. A special protocol assessment that will expand the study from 150 to 300 patients is anticipated.

Full Story: